SHE — Shedir Pharma Srl Unipersonale Balance Sheet
0.000.00%
- €55.45m
- €52.75m
- €59.39m
- 97
- 81
- 95
- 100
Annual balance sheet for Shedir Pharma Srl Unipersonale, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 6.1 | 16.4 | 19.1 | 15.8 | 1.23 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 14 | 12.1 | 12.2 | 16.1 | 17.6 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 34.9 | 40.8 | 40.7 | 44.1 | 41.9 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 6.64 | 5.97 | 5.88 | 5.05 | 7.84 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 47.8 | 52.7 | 52.6 | 56.8 | 56.1 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 17.2 | 12.6 | 14.4 | 16.4 | 14.4 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 25.3 | 26.1 | 24.5 | 24 | 20.2 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Other Equity | |||||
| Total Equity | 22.6 | 26.7 | 28.1 | 32.8 | 36 |
| Total Liabilities & Shareholders' Equity | 47.8 | 52.7 | 52.6 | 56.8 | 56.1 |
| Total Common Shares Outstanding |